The manufacturing of biopharmaceuticals can be challenging as of the preservation of the Active Pharmaceutical Ingredients (API). In fact, the various processing steps may cause different levels of denaturation and hence aggregation, resulting in massive loss of product. Currently, the aggregation phenomena are detected through off-line procedures which can take up to days and, thus, incompatible with the implementation of corrective actions on the manufacturing process to preserve the API integrity. In this thesis project, various Process Analytical Technologies (PAT) are compared for the online and inline detection of the protein aggregation during the manufacturing process. This analysis was carried out upon two model products, identified within the GSK portfolio.